BDRX News

Result of General Meeting

Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France

Biodexa lance des activités de soutien aux patients atteints de polypose adénomateuse familiale (PAF) et aux centres de traitement en France

Result of Annual General Meeting

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants

Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress

Postponement and Re-scheduling of Annual General Meeting

Biodexa issues letter to Shareholders

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

Tanner Pharma Group y Biodexa lanzan un programa de acceso anticipado global para pacientes de poliposis adenomatosa familiar